IPOs: The 5 Best New Stocks of Q1 2014

Pharmaceutical companies dominate the list of best IPOs

     

New Stocks — Ultragenyx Pharmaceutical (RARE)

Ultragenyx 185 IPOs: The 5 Best New Stocks of Q1 2014IPO Return: 162.1%

Ultragenyx Pharmaceutical (RARE) is biotech operator that focuses on rare diseases. The initial target is on serious, debilitating metabolic genetic diseases.

Over the past few years, the company has obtained in-licensed treatments for five different disorders. And they will hit Phase 1 or Phase 2 clinical trials this year. The company thinks this approach will be quicker — and cheaper.

A key to Ultragenyx is biologics, which involves monoclonal antibody and enzyme replacement therapies. Enzymes are used to process normal cell functions. So, if there is a breakdown, the results can be devastating. But Ultragenyx believes it has an effective way to replace those that malfunction. And with a return of more than 160%, RARE earns the top spot for best new stocks of 2014.

Tom Taulli runs the InvestorPlace blog IPO Playbook. He is also the author of High-Profit IPO StrategiesAll About Commodities and All About Short Selling. Follow him on Twitter at @ttaulli. As of this writing, he did not hold a position in any of the aforementioned securities.

1 2 3 4 5 6 View All
 

Article printed from InvestorPlace Media, http://investorplace.com/ipo-playbook/ipos-best-new-stocks-q1-2014/.

©2014 InvestorPlace Media, LLC

Comments are currently unavailable. Please check back soon.